Association between rs13266634 C/T polymorphisms of solute carrier family 30 member 8 (SLC30A8) and type 2 diabetes, impaired glucose tolerance, type 1 diabetes—A meta-analysis

详细信息    查看全文

• 作者：Kuanfeng Xu^a ; ¹ ; ^{bio97xkf@163.com} ; Min Zha^a ; ¹ ; ^{zhamin16@163.com} ; Xiaohong Wu^a ; ¹ ; ^{drxhwu@163.com} ; Zhangbin Yu^b ; ² ; ^{yuzhangbin@126.com} ; Rongbin Yu^c ; ³ ; ^{rongbinyu@njmu.edu.cn} ; Xinyu Xu^a ; ¹ ; ^{xinyuxu@163.com} ; Heng Chen^a ; ¹ ; ^{chenheng1985@126.com} ; Tao Yang^a ; ^{yangt@njmu.edu.cn}
• 关键词：SLC30A8 ; Type 2 diabetes ; Type 1 diabetes ; Impaired glucose tolerance ; Meta-analysis
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2011
• 出版时间：February 2011
• 年：2011
• 卷：91
• 期：2
• 页码：195-202
• 全文大小：352 K

文摘

Aims

To investigate the association of solute carrier family 30 member 8 (SLC30A8) rs13266634 C/T polymorphism with type 2 diabetes (T2DM), impaired glucose tolerance (IGT), and type 1 diabetes (T1DM).

Methods

We searched all the publications about the association between SLC30A8 and diabetes from PubMed, and evaluated the association between SLC30A8 rs13266634 C/T polymorphism and T2DM, IGT and T1DM, respectively, by meta-analysis of all the validated studies. Allelic and genotypic comparisons between cases and controls were evaluated.

Results

Thirty six studies were included in the meta-analysis: 31 studies were analysed for rs13266634 C/T polymorphism with T2DM, 3 studies with IGT and 4 studies with T1DM. The pooled odds ratios (ORs) for allelic and genotypic comparisons (including additive model, co-dominant model, dominant model and recessive model) showed that rs13266634 C/T polymorphism was significantly associated with increased T2DM risk: OR = 1.15, 95 % confidence interval (CI) = 1.13–1.17, P < 0.001, P_{heterogeneity} = 0.041, OR = 1.34, 95 % CI = 1.26–1.41, P < 0.001, P_{heterogeneity} = 0.908, OR = 1.20, 95 % CI = 1.16–1.24, P < 0.001, P_{heterogeneity} = 0.699, and OR = 1.23, 95 % CI = 1.17–1.30, P < 0.001, P_{heterogeneity} = 0.801, respectively. In subgroup analyses, we found that rs13266634 C/T polymorphism was associated with T2DM risk both in Asian and European subgroup (P < 0.001), but not in African (P > 0.05). And the pooled odds ratio (OR) for allelic frequency comparison showed that rs13266634 C/T polymorphism was also significantly associated with IGT: OR = 1.15, 95 % CI = 1.06–1.26, P < 0.001, P_{heterogeneity} = 0.364. Meanwhile, our meta-analysis did not suggest that rs13266634 C/T polymorphism was associated with T1DM risk (P > 0.05): OR = 1.02, 95 % CI = 0.98–1.06, P = 0.328, P_{heterogeneity} = 0.488 for allelic frequency comparison.

Conclusions

Our meta-analysis results revealed the significant association between rs13266634 C/T polymorphism and T2DM and IGT, but did not support the association between this polymorphism and T1DM.